[#item_full_content]
BOSTON–(BUSINESS WIRE)–SOUFFLÉ THERAPEUTICS, INC. (“Soufflé™” or “Company”), a leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives, today announced the close of an oversubscribed $135 million Series B financing. The round was led by Juvia Group and welcomes leading institutional investors TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management, and a Leading Sovereign